Strategies and limitations in dendrimeric immunogen synthesis. The influenza virus M2e epitope as a case study
- PMID: 20025260
- DOI: 10.1021/bc9003316
Strategies and limitations in dendrimeric immunogen synthesis. The influenza virus M2e epitope as a case study
Abstract
Dendrimeric platforms such as multiple antigen peptides (MAPs) are regarded as one of the most efficacious approaches for antigenic presentation. Originally described as available by stepwise solid-phase peptide synthesis (SPPS), MAPs have also been prepared by chemical (thioether, oxime, hydrazone) ligation of appropriately functionalized tetra- or octavalent polylysine scaffolds with the peptide antigen to be multiply displayed. In this work, the advantages and limitations of two of the most frequent methods of MAP preparation, namely, chemoselective thioether ligation in solution, and all-solid-phase synthesis, have been tested in the case of a particularly troublesome epitope model, the ectodomain of protein M2 from influenza virus (M2e). The strong tendency of M2e to self-associate is a serious inconvenient for conjugation in solution, which as a result fails to produce the target MAPs with the specified number of M2e copies. In contrast, the fully stepwise SPPS approach is shown to be quite practical, especially when 6-aminohexanoic acid spacer units providing increased internal flexibility are inserted at each branching point.
Similar articles
-
Synthesis of multiple antigenic peptides (MAPs)-strategies and limitations.J Pept Sci. 2011 Apr;17(4):247-51. doi: 10.1002/psc.1310. Epub 2010 Nov 29. J Pept Sci. 2011. PMID: 21391284
-
Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.Immunol Lett. 2004 May 15;93(2-3):131-6. doi: 10.1016/j.imlet.2004.03.003. Immunol Lett. 2004. PMID: 15158608
-
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.Vaccine. 2008 Jan 10;26(2):201-14. doi: 10.1016/j.vaccine.2007.10.062. Epub 2007 Nov 20. Vaccine. 2008. PMID: 18063235
-
Soluble recombinant influenza vaccines.Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1961-3. doi: 10.1098/rstb.2001.0980. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11779398 Free PMC article. Review.
-
A "universal" human influenza A vaccine.Virus Res. 2004 Jul;103(1-2):173-6. doi: 10.1016/j.virusres.2004.02.030. Virus Res. 2004. PMID: 15163506 Review.
Cited by
-
Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood-brain barrier transport.Chem Sci. 2018 Sep 18;9(44):8409-8415. doi: 10.1039/c8sc02415d. eCollection 2018 Nov 28. Chem Sci. 2018. PMID: 30542590 Free PMC article.
-
Peptide-Based Vaccines: Foot-and-Mouth Disease Virus, a Paradigm in Animal Health.Vaccines (Basel). 2021 May 8;9(5):477. doi: 10.3390/vaccines9050477. Vaccines (Basel). 2021. PMID: 34066901 Free PMC article. Review.
-
Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.Nanomedicine (Lond). 2014 Feb;9(2):237-51. doi: 10.2217/nnm.13.58. Epub 2013 Jul 5. Nanomedicine (Lond). 2014. PMID: 23829488 Free PMC article.
-
Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry.Biosci Rep. 2019 Sep 24;39(9):BSR20192196. doi: 10.1042/BSR20192196. Print 2019 Sep 30. Biosci Rep. 2019. PMID: 31477581 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
